J&J's ICOTYDE Shows 49% Complete Skin Clearance at 52 Weeks in Psoriasis
One-year Phase 3 data at AAD 2026 show ICOTYDE (icotrokinra) achieves 49% complete clearance at Week 52, with nearly 60% in adolescents. No new safety signals.
#johnson-johnson
2 stories
FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis
J&J's icotrokinra (Icotyde) approved for moderate-to-severe plaque psoriasis, with ~70% of patients achieving clear or almost clear skin by week 16.